PLoS ONE, 2015 AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts +5 more
doaj +1 more source
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2017 The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj +1 more source
The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]
, 2013 The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Alex C. Conner +13 more
core +2 more sources
Cyclic AMP signalling in pancreatic islets [PDF]
, 2010 Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian +2 more
core +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Cutting Edge Developments in Diabetes
Diabetology, 2023 Since 2005, glucagon-like peptide 1 (GLP-1) receptor agonists have been clinically available, which has resulted in a significant transformation in diabetes care, both in terms of weight management and glucose control [...]
Peter M. Clifton
doaj +1 more source
Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]
, 2016 Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst +63 more
core +3 more sources
Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review
Терапевтический архив, 2023 A review of publications devoted to the analysis of genetic polymorphisms of the gene encoding the glucagon-like peptide type 1 receptor and some other genes directly and indirectly involved in the implementation of its physiological action is presented.
Evgenya L. Golovina +6 more
doaj +1 more source
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]
, 2018 Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V. +9 more
core +1 more source
The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. [PDF]
, 2017 ObjectiveThe differential effect of GLP-1 agonist Exenatide on functional connectivity of the nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on appetite-related behaviours was investigated in women with normal weight ...
Connolly, L +7 more
core +3 more sources